Abstract:Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulators MDM2 and MDMX activates P53 in vitro and in vivo, representing a viable therapeutic strategy for cancer treatment. Using phage display techniques, we previously identified a potent peptide activator of P53, termed PMI (TSFAEYWNLLSP), with binding affinities for both MDM2 and MDMX in the low nanomolar concentration range. Here we report an ultrahigh affinity, dual-specificity peptide antagonist of MDM2 and MDMX obtained through systematic mutational analysis and additivity-based molecular design. Functional assays of over 100 peptide analogs of PMI using surface plasmon resonance and fluorescence polarization techniques yielded a dodecameric peptide termed PMI-M3 (LTFLEYWAQLMQ) that bound to MDM2 and MDMX with Kd values in the low picomolar concentration range as verified by isothermal titration calorimetry. Co-crystal structures of MDM2 and of MDMX in complex with PMI-M3 were solved at 1.65 and 3.0 Å resolution, respectively. Similar to PMI, PMI-M3 occupied the P53-binding pocket of MDM2/MDMX, which was dominated energetically by intermolecular interactions involving Phe3, Tyr6, Trp7, and Leu10. Notable differences in binding between PMI-M3 and PMI were observed at other positions such as Leu4 and Met11 with MDM2, and Leu1 and Met11 with MDMX, collectively contributing to a significantly enhanced binding affinity of PMI-M3 for both proteins. By adding lysine residues to both ends of PMI and PMI-M3 to improve their cellular uptake, we obtained modified peptides termed PMI-2K (KTSFAEYWNLLSPK) and M3-2K (KLTFLEYWAQLMQK). Compared with PMI-2K, M3-2K exhibited significantly improved antitumor activities in vitro and in vivo in a P53-dependent manner. This super-strong peptide inhibitor of the P53-MDM2/MDMX interactions may become, in its own right, a powerful lead compound for anticancer drug development, and can aid molecular design of other classes of P53 activators as well for anticancer therapy.

Stapled peptides with improved potency and specificity that activate p53

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery

Bicyclic Stapled Peptides Based on P53 As Dual Inhibitors for the Interactions of P53 with MDM2 and MDMX

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Small Molecule Inhibitors of the P53-Mdm2

Investigating peptide sequence variations for ‘double-click’stapled p53 peptides

Design, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity In Vivo

A Dimethylbromobenzene-Cysteine Stapled Peptide Dual Inhibitor of the P53-Mdm2/mdmx Interactions

D-Peptide Inhibitors of the P53-Mdm2 Interaction for Targeted Molecular Therapy of Malignant Neoplasms

Functionalised staple linkages for modulating the cellular activity of stapled peptides

P53 Alpha-Helix Mimetics Antagonize P53/mdm2 Interaction and Activate P53.

Identification of novel mdm2 binding peptides by phage display.

Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors

P53 Α-Helix Mimetics Antagonize P53/mdm2 Interaction and Activate P53

Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX.

Α-Helix-mimicking Sulfono-γ-AApeptide Inhibitors for P53–mdm2/mdmx Protein–Protein Interactions

190 Novel Classes of P53 Activators for Cancer Therapy

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics